Temporins
What the Research Actually Shows
Human: 0 studies, 3 groups · Animal: 0 · In Vitro: 2
At just ten to thirteen amino acids, temporins from frog skin are the smallest antimicrobial peptides ever discovered—and they kill bacteria that resist our best drugs
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
Temporins are tiny antimicrobial peptides—just 10 to 13 amino acids long—isolated from the skin of European frogs. They are the smallest antimicrobial peptides known from any animal source. In laboratory studies, temporins kill bacteria including drug-resistant strains, and some variants also kill fungi and cancer cells. But no temporin has ever been tested in a human being. The most promising family members have hemolytic activity—they damage red blood cells along with bacteria—which limits their therapeutic potential. These peptides are research tools, not drug candidates.
In 1996, a team of Italian researchers scraped secretions from the skin of the European red frog (*Rana temporaria*) and found something remarkable: a family of antimicrobial peptides so small they seemed to break the rules. At 10 to 13 amino acids, temporins are roughly half the size of most antimicrobial peptides—yet they kill bacteria with efficiency that rivals much larger molecules.
The temporin family is enormous. More than 100 variants have been isolated from different frog species, creating a natural library of structure-activity relationships that medicinal chemists can mine for drug design principles. Temporin A and Temporin B show strong anti-Gram-positive activity with manageable toxicity. Temporin L has the broadest spectrum—active against Gram-negative bacteria as well—but comes with significant hemolytic activity that makes it a poor drug candidate as-is.
Despite three decades of characterization, no temporin has entered clinical development. The compounds remain research-grade peptides studied in academic laboratories. This article reviews what the science actually shows—and why being nature's smallest antibiotic has not been enough to reach a patient.
In This Article
Quick Facts: Temporins at a Glance
Type
Short cationic amphipathic peptides, 10–13 amino acids, C-terminal amidation
Also Known As
Temporin A, Temporin B, Temporin L; frog skin antimicrobial peptides
Molecular Weight
~1,300–1,600 Da (varies by variant)
Peptide Sequence
Temporin A: FLPLIGRVLSGIL-NH₂ (13 amino acids)
Source
Skin secretions of *Rana temporaria* (European red frog) and related species
Discovery
Simmaco et al., 1996 (PMID 9022710)
Primary Molecular Function
Alpha-helical membrane insertion → bacterial membrane permeabilization
Structure
Linear, no disulfide bonds; adopts alpha-helical conformation at membrane surfaces
Antimicrobial Spectrum
Gram-positive bacteria (S. aureus, S. pyogenes), fungi (Candida); Temporin L also active against Gram-negatives
Family Size
>100 natural variants isolated from multiple frog species
Key Advantage
Smallest known AMPs—cheaper to synthesize, potentially better tissue penetration
Clinical Programs
None. No clinical development for any temporin variant.
Route
Not applicable—research-grade peptides studied in vitro only
Hemolytic Activity
Variable: Temporin L (high), Temporin A (moderate), Temporin B (low)
FDA Status
Not approved. No clinical development.
WADA Status
Not on Prohibited Lists
Evidence Tier
4 Preclinical Only
Verdict
Eyes Open
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Are Temporins?
A frog sits in a pond thick with bacteria, fungi, and parasites. Its skin is wet, thin, and permeable—the worst possible barrier against infection. And yet the frog thrives. Part of the reason is a chemical arsenal secreted directly from skin glands: cocktails of antimicrobial peptides that kill pathogens before they can breach the surface. Among these peptides, temporins stand out for one reason—they are impossibly small.
The Smallest Antimicrobial Peptides
Most antimicrobial peptides are 20 to 50 amino acids long. Temporins are 10 to 13. This makes them the smallest antimicrobial peptides isolated from any vertebrate. Their compact size was initially surprising—researchers assumed that a certain minimum length was required for the alpha-helical conformation that drives membrane disruption. Temporins proved otherwise. They adopt amphipathic alpha-helical structures at bacterial membrane surfaces despite their small size, and they kill bacteria effectively.
PLAIN ENGLISH
Most natural antibiotics from animals are 20 to 50 building blocks long. Temporins are only 10 to 13—roughly the size of a large word rather than a sentence. Despite being tiny, they still fold into the right shape to punch holes in bacterial walls.
The Family
More than 100 temporin variants have been isolated from frog species worldwide. The three most studied are Temporin A (anti-Gram-positive, moderate toxicity), Temporin B (anti-Gram-positive, low toxicity—best therapeutic profile), and Temporin L (broadest spectrum but significant hemolytic activity). This natural diversity provides a rich structure-activity relationship (SAR) library for drug designers.
Origins and Discovery
Temporins were discovered in 1996 by Maurizio Simmaco and colleagues at the University of Rome, who analyzed skin secretions of Rana temporaria—the common European red frog (PMID 9022710). The researchers identified a novel family of antimicrobial peptides that were dramatically smaller than any previously characterized from vertebrate sources.
The discovery built on the broader revolution in antimicrobial peptide biology that Michael Zasloff had catalyzed in 1987 with his discovery of magainins from African clawed frog skin. By the mid-1990s, multiple research groups were systematically surveying amphibian skin secretions, and the Italian team's work on R. temporaria revealed that nature had found an even more economical solution to the microbial defense problem than anyone expected.
The name "temporin" derives from the species name Rana temporaria. Subsequent surveys of other frog species—including Rana ornativentris in Japan and Rana esculenta in Europe—revealed that temporin-like peptides were widespread across amphibia, suggesting an ancient and evolutionarily successful defense strategy.
Mechanism of Action
Alpha-Helical Membrane Permeabilization
Temporins are unstructured in aqueous solution but adopt amphipathic alpha-helical conformations when they encounter a lipid membrane. The amphipathic helix has a hydrophobic face that inserts into the lipid bilayer and a cationic face that interacts with anionic bacterial membrane phospholipids.
The mechanism follows the general model for alpha-helical antimicrobial peptides: at low concentrations, temporins lie parallel to the membrane surface (carpet model); at higher concentrations, they insert perpendicularly and form transient pores. The pores allow ion efflux, dissipation of membrane potential, and ultimately bacterial death.
PLAIN ENGLISH
In water, temporins are floppy and shapeless. But when they encounter a bacterial membrane, they snap into a spiral shape—like a corkscrew. One side of the corkscrew is water-repelling (it dives into the oily membrane) and the other side is electrically charged (it grabs onto the membrane surface). This corkscrew action tears holes in the bacterium's wall.
Selectivity Problem
The selectivity of temporins—their ability to distinguish bacterial membranes from mammalian membranes—varies significantly across the family. Temporin B has good selectivity: it kills bacteria at concentrations well below those that damage red blood cells. Temporin L has poor selectivity: it kills bacteria efficiently but also lyses red blood cells at similar concentrations (hemolytic activity). Temporin A falls in between.
This selectivity variation provides valuable SAR data. By comparing the sequences and structures of high-selectivity variants (Temporin B) with low-selectivity variants (Temporin L), researchers can identify the structural features that determine therapeutic index.
Additional Activities
Some temporins show antifungal activity (against Candida albicans), anti-parasitic activity (against Leishmania), and anticancer activity in cell culture. These are early-stage observations from in vitro studies.
Key Research Areas and Studies
Structure-Activity Relationships
The large temporin family provides a natural SAR experiment. Rinaldi et al. (2002; PMID 10691983) systematically compared temporin variants and identified key structural determinants of antimicrobial activity and selectivity. The ratio of cationic to hydrophobic residues, the depth of membrane insertion, and the strength of the amphipathic moment all correlate with biological activity profiles.
Temporin L — Broad Spectrum but Hemolytic
Mangoni et al. (2002; PMID 12133008) characterized Temporin L as the first temporin with significant activity against Gram-negative bacteria—a property most temporins lack because the outer membrane of Gram-negative bacteria acts as a permeability barrier. Temporin L overcomes this barrier, but at the cost of increased hemolytic activity. Understanding why Temporin L penetrates both barriers while others cannot is an active area of research.
Engineered Analogs
Several research groups have designed temporin analogs with improved therapeutic profiles—enhanced antimicrobial potency, reduced hemolytic activity, or increased stability. These engineered variants are published in academic literature but have not entered formal preclinical development pipelines.
PLAIN ENGLISH
Scientists are trying to redesign temporins to keep the bacteria-killing power while removing the blood-cell-damaging side effect. They are using the natural variation across 100+ temporin variants as a blueprint. So far, the redesigns work in test tubes but have not been tested in animals or humans.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “"Temporins kill drug-resistant bacteria"” | Temporin A and B are active against S. aureus (including some resistant strains) in vitro. MIC data published. Never tested in an infection model. | Preclinical Only |
| “"Temporins are the smallest natural antibiotics"” | Correct. At 10–13 amino acids, temporins are the smallest vertebrate-derived AMPs documented. This is an established structural fact. | Supported |
| “"Temporins could treat wound infections"” | Theoretical. No wound infection study has been conducted—in animals or humans. The topical application concept is based on the frog's natural use of these peptides for skin defense. | Theoretical |
| “"Temporin L kills Gram-negative bacteria"” | Confirmed in vitro (Mangoni et al., 2002; PMID 12133008). However, Temporin L also has significant hemolytic activity, limiting therapeutic relevance. | Mixed Evidence |
| “"Temporins don't cause resistance"” | Membrane-targeting mechanism makes resistance difficult in theory. No resistance studies have been published for temporins specifically. The claim is extrapolated from general AMP biology. | Theoretical |
| “"Temporin B has the best therapeutic profile"” | Among natural temporins, Temporin B has the best selectivity index (high antimicrobial activity, low hemolytic activity). This is supported by in vitro comparison studies. | Preclinical Only |
| “"Temporins have anticancer properties"” | Some variants show cytotoxicity against cancer cell lines in vitro. No animal cancer model has been tested. The finding is preliminary. | Preclinical Only |
| “"Temporins could be developed into drugs"” | Possible in principle. But three decades after discovery, no company or academic group has advanced a temporin into formal preclinical development. The market incentive is low for a non-patentable natural peptide class. | Theoretical |
| “"Frog skin peptides are the future of antibiotics"” | Amphibian skin has yielded interesting lead compounds (magainins → pexiganan). But pexiganan—the most advanced AMP from frog skin—was denied FDA approval twice. The track record is instructive, not encouraging. | Mixed Evidence |
| “"Temporins kill fungal infections"” | Some variants show anti-Candida activity in vitro. No animal fungal infection model has been tested. | Preclinical Only |
| “"Temporins are safer than conventional antibiotics"” | Unknown. No safety data exists in animals or humans. Hemolytic activity of some variants suggests the opposite for systemic use. | Unsupported |
| “"Temporins synergize with other antimicrobials"” | Limited in vitro data suggests additive or synergistic effects with some conventional antibiotics. Not replicated or tested in vivo. | Preclinical Only |
We currently don’t have any vetted partners for this compound. Check back soon.
The Human Evidence Landscape
There are no human studies of temporins—not clinical trials, not observational studies, not case reports. No temporin has ever been administered to a human being for any purpose.
What Animal Research Exists
Animal studies are also extremely limited. The vast majority of temporin research is in vitro—testing peptides against bacteria in culture. A small number of studies have explored temporins in animal wound or infection models, but these are preliminary and do not constitute a preclinical development package.
Why the Gap
Several factors explain why temporins have not advanced toward clinical testing:
Hemolytic activity. The most potent temporins (Temporin L) are also the most toxic to red blood cells. Engineering selectivity into these small peptides is challenging—there are very few amino acid positions to modify.
Market economics. Natural peptides from frog skin are difficult to patent in ways that support pharmaceutical development. Without strong intellectual property protection, the commercial incentive to invest in clinical development is weak.
Competition. Pexiganan—the most clinically advanced amphibian-derived AMP—failed FDA approval twice. This precedent makes it difficult to attract investment for another frog-derived peptide.
PLAIN ENGLISH
No one has ever given a temporin to a person. The most honest explanation is a combination of scientific challenges (some temporins damage blood cells) and business realities (there is no clear path to making money from developing these peptides as drugs).
Safety, Risks, and Limitations
Hemolytic Activity—The Central Safety Concern
The defining safety issue for temporins is hemolytic activity—the tendency of some variants to lyse red blood cells. Temporin L, the most potent antimicrobial variant, has the highest hemolytic activity. Temporin B has the lowest. The therapeutic index (ratio of hemolytic concentration to antimicrobial concentration) varies from poor (Temporin L) to acceptable (Temporin B) depending on the specific variant.
No Safety Data in Vivo
No animal toxicology study has been published for any temporin. No maximum tolerated dose, no pharmacokinetic profile, no organ toxicity assessment. The safety profile is entirely inferred from in vitro hemolysis and cytotoxicity assays.
Stability Concerns
Small peptides in biological fluids are subject to rapid proteolytic degradation. Temporins may have very short half-lives in vivo, requiring frequent dosing or formulation strategies to maintain therapeutic concentrations.
CRITICAL DISCLAIMER
No animal or human safety data exists for temporins. Hemolytic activity of several family members is a documented concern from in vitro studies.
Legal and Regulatory Status
FDA Status
No FDA status. Temporins are not under investigation and no IND application has been filed for any temporin variant.
Research Classification
Available as research-grade reagents from peptide synthesis companies. Not marketed as supplements, drugs, or health products.
WADA Status
Not on the World Anti-Doping Agency Prohibited List. No performance-enhancing claims exist.
Research Protocols and Formulation Considerations
Laboratory Research Only
Temporin research is conducted using synthetic peptides, typically synthesized by solid-phase peptide synthesis (SPPS) with C-terminal amidation. Research-grade purity is typically ≥95%. No formulation has been optimized for in vivo use.
Simplicity Advantage
Unlike defensins (which require disulfide bond formation), temporins are linear peptides with no disulfide bonds. This makes them relatively inexpensive and straightforward to synthesize—an advantage for research and a potential advantage for manufacturing if therapeutic development ever occurs.
Dosing in Published Research
The following table summarizes dosing protocols for Temporins as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.
In Vitro Parameters
Published MIC values for Temporin A against S. aureus range from 4 to 32 μg/mL depending on the strain. Temporin B has similar activity against Gram-positive organisms. Temporin L shows broader spectrum with MICs in the 2–16 μg/mL range against both Gram-positive and Gram-negative bacteria.
No In Vivo Dosing
No animal dosing study has established effective doses for infection treatment. The translation from in vitro MIC to in vivo therapeutic dose is unknown.
Dosing in Self-Experimentation Communities
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
WHY IS THIS SECTION NEARLY EMPTY?
Temporins has limited community usage data. Unlike more widely-used research peptides, there are few reliable community reports on dosing protocols. We include this section for completeness but cannot populate it with data we do not have. As community experience grows, we will update this section accordingly.
Temporins are not available from peptide vendors serving the biohacker or self-experimentation community. They have no presence on forums, social media, or gray-market peptide platforms. These are purely academic research compounds.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into Temporins combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining Temporins with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
| Compound | Type | Evidence Tier | Verdict | Primary Mechanism | Source | Spectrum | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|---|
| Alpha-Defensins | Cationic AMP (29–35 aa, 3 disulfide bonds) | Tier 4 — Preclinical Only | Eyes Open | Membrane permeabilization + immunomodulation | Endogenous — neutrophil azurophilic granules (HNP-1/2/3) and Paneth cells (HD-5/6) | Gram+, Gram−, fungi, viruses | None therapeutic; diagnostic biomarker use (synovial fluid) | Not approved | Not prohibited | No therapeutic development; hemolytic at high concentrations |
| Beta-Defensins | Cationic AMP (41–50 aa, 3 disulfide bonds) | Tier 4 — Preclinical Only | Eyes Open | Membrane permeabilization + chemotaxis of DCs/T cells | Endogenous — epithelial cells at all mucosal surfaces | Gram+ (HBD-1/2), broad including MRSA (HBD-3) | None therapeutic | Not approved | Not prohibited | No therapeutic development; defensin overexpression linked to inflammatory diseases |
| Temporins | Short cationic AMP (10–13 aa, C-terminal amide) | Tier 4 — Preclinical Only | Eyes Open | Alpha-helical membrane insertion → permeabilization | Rana temporaria (European red frog) skin secretions | Gram+ (primary), some Gram− (Temporin L), fungi | None | Not approved | Not prohibited | Hemolytic activity varies by variant; no development program |
| Magainins | Cationic alpha-helical AMP (23 aa) | Tier 4 — Preclinical Only | Eyes Open | Toroidal pore formation in bacterial membranes | Xenopus laevis (African clawed frog) skin — Zasloff 1987 | Broad: Gram+, Gram−, fungi, protozoa | None (derivative pexiganan went to Phase III) | Not approved | Not prohibited | Superseded by engineered analog pexiganan; no independent development |
| Pexiganan | Synthetic magainin 2 analog (22 aa) | Tier 2 — Clinical Trials | Eyes Open | Enhanced alpha-helical membrane permeabilization | Synthetic — SAR optimization of magainin 2 by Zasloff/Magainin Pharmaceuticals | Broad: Gram+/−, aerobes, anaerobes (2,515 DFU isolates tested) | Phase III complete (N=835); FDA denied 1999 (non-superiority); LEADER trials failed ~2016 | Not approved (twice denied) | Not prohibited | Equivalent but not superior to ofloxacin; FDA required superiority for novel class |
| Nisin | Lantibiotic (34 aa, post-translationally modified) | Tier ~ — It's Complicated | Reasonable Bet | Lipid II binding (blocks cell wall) + pore formation (membrane disruption) | Lactococcus lactis — discovered 1928, commercialized 1953 | Gram+ (MRSA, VRE, C. diff); limited Gram− | None pharmaceutical; 70+ years food use | GRAS for food (1988); not approved as drug | Not prohibited | GRAS for food only; no pharmaceutical clinical trial despite 70 years of safe food use |
style="color:#0F4C5C;font-size:28px;font-weight:700;margin:48px 0 16px 0;line-height:1.2">Frequently Asked Questions
What are temporins?
Why are temporins so small compared to other antimicrobial peptides?
Can temporins kill antibiotic-resistant bacteria?
What is the difference between Temporin A, B, and L?
Are temporins available for purchase?
How do temporins compare to magainins?
Why haven't temporins been developed into drugs?
Do temporins work against fungal infections?
What makes frog skin such a good source of antibiotics?
Could engineered temporins be better than natural ones?
How are temporins related to the antibiotic resistance crisis?
Is there any human safety data for temporins?
Summary of Key Findings
Temporins are the smallest antimicrobial peptides known from any vertebrate source—10 to 13 amino acids isolated from European frog skin. The family includes more than 100 natural variants, providing a rich structure-activity library. In vitro, temporins kill Gram-positive bacteria (including drug-resistant strains), and Temporin L additionally kills Gram-negative bacteria and fungi.
The central limitation is the gap between in vitro activity and therapeutic viability. The most potent variants are also the most hemolytic. No temporin has been tested in an animal infection model with rigor, and no clinical trial has been conducted. Three decades after discovery, these peptides remain academic research tools. The natural diversity of the family continues to inform antimicrobial peptide design, but temporins themselves are unlikely to become drugs.
PLAIN ENGLISH
Temporins are tiny bacteria-killing peptides from frog skin. They work well in a test tube, but some of them also damage human blood cells. Nobody has ever given them to a person, and no drug company is trying to develop them.
Verdict Recapitulation
Temporins are scientifically interesting—the smallest AMPs in nature, with a family diversity that informs drug design. But they have not progressed toward clinical use and face significant barriers (hemolytic activity, economics, precedent). They are worth watching as a source of design principles for future antimicrobial drugs, not as therapeutic candidates themselves.
For readers considering Temporins, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source Temporins
Further Reading and Resources
If you want to go deeper on Temporins, the evidence landscape for antimicrobial peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Antimicrobial Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: Temporins — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Simmaco, M., et al. (1996). "Temporins, antimicrobial peptides from the European red frog Rana temporaria." Eur J Biochem, 242(3), 788–792. PMID 9022710
- Mangoni, M. L., et al. (2002). "Temporin L: antimicrobial, haemolytic and cytotoxic activities, and effects on membrane permeabilization in lipid vesicles." Biochem J, 334(Pt 3), 733–741. PMID 12133008
- Rinaldi, A. C., et al. (2002). "Antimicrobial peptides from amphibian skin: an expanding scenario." Curr Opin Chem Biol, 6(6), 799–804. PMID 10691983
- Zasloff, M. (2002). "Antimicrobial peptides of multicellular organisms." Nature, 415(6870), 389–395. PMID 11807749
DISCLAIMER
Temporins is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 11, 2026. Next scheduled review: October 08, 2026.
About the Author
Lawrence Winnerman
Founder of Peptidings.com. Former big tech product manager. Independent peptide researcher focused on translating clinical evidence into accessible science.